Tags

Type your tag names separated by a space and hit enter

Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.

Abstract

PURPOSE

To evaluate whether use of a bisphosphonate (risedronate) in addition to calcium and vitamin D in male veterans with epilepsy who were taking antiepileptic drugs (AEDs) long term can prevent the loss of bone mass (BMD, bone mineral density) associated with AED use compared to patients who were treated with a placebo plus calcium and vitamin D. As a secondary end point we studied the incidence of new morphometric vertebral and nonvertebral fractures.

METHODS

Antiepileptic drug and osteoporosis prevention trial (ADOPT) was designed as a prospective 2-year double-blind, randomized placebo controlled study involving 80 male veterans with epilepsy who were being treated with AEDs such as phenytoin, phenobarbital, sodium valproate, or carbamazepine for a minimum of 2 years. All enrolled participants received calcium and vitamin D supplementation, and were randomized to risedronate or matching placebo. Total body, bilateral proximal femora, and anteroposterior (AP) lumbar spine BMDs in addition to morphometric lateral vertebral assessments (LVAs) were evaluated by a dual energy x-ray absorptiometry (DXA) instrument. Comparisons of BMDs were made between baseline, 1 year, and after 2 years of enrollment in the study. The incidence of new vertebral and nonvertebral fractures was secondary end point.

KEY FINDINGS

Of the 80 patients initially enrolled in the study, 53 patients completed the study. Baseline characteristics of the two groups were similar. At the end of the study, in the placebo plus calcium and vitamin D group, we observed a significant improvement in BMD at any of the evaluated sites when compared to their baseline scans in 69% (18/26) of the participants. In the risedronate plus calcium and vitamin D group, we observed significant improvement of BMDs in 70% (19/27) of the participants. At the end of the study, the risedronate group experienced a significant increase of BMD at the lumbar spine L1-4 (1.267-1.332 g/cm(2)), which was significantly larger than that seen in the placebo group) (1.229 g/cm(2) vs. 1.245 g/cm(2) ; p = 0.0066).There were nonsignificant differences between the two groups regarding changes of total body BMD or at the proximal bilateral femora. Five new vertebral fractures and one nonvertebral fracture were observed only in the placebo group.

SIGNIFICANCE

Calcium and vitamin D supplementation or calcium and vitamin D supplementation in addition to risedronate improved BMD in more than 69% of male veterans with epilepsy who were taking AEDs. In the group receiving risedronate plus calcium and vitamin D there was a significant improvement of BMD at the lumbar spine as compared to the placebo group, which also received calcium and vitamin D. The use of risedronate plus calcium and vitamin D prevented the incidence of new vertebral fractures and one nonvertebral fracture in this cohort.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Primary Care Service, Boston VA Healthcare System, Boston, Massachusetts, U.S.A; Osteoporosis Clinic, Boston VA Healthcare System, Boston, Massachusetts, U.S.A; Rheumatology Section, Boston VA Healthcare System, Boston, Massachusetts, U.S.A; Department of Medicine, Boston VA Healthcare System, Boston, Massachusetts, U.S.A; Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, U.S.A; Department of Medicine, Harvard Medical School, Boston, Massachusetts, U.S.A.

    , , , , ,

    Source

    Epilepsia 54:11 2013 Nov pg 1997-2004

    MeSH

    Adult
    Aged
    Aged, 80 and over
    Anticonvulsants
    Bone Density
    Bone Density Conservation Agents
    Calcium, Dietary
    Chronic Disease
    Diphosphonates
    Double-Blind Method
    Epilepsy
    Humans
    Male
    Middle Aged
    Osteoporosis
    Osteoporotic Fractures
    Prospective Studies
    Spinal Fractures
    Treatment Outcome
    Vitamin D

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    24010637

    Citation

    Lazzari, Antonio A., et al. "Prevention of Bone Loss and Vertebral Fractures in Patients With Chronic Epilepsy--antiepileptic Drug and Osteoporosis Prevention Trial." Epilepsia, vol. 54, no. 11, 2013, pp. 1997-2004.
    Lazzari AA, Dussault PM, Thakore-James M, et al. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial. Epilepsia. 2013;54(11):1997-2004.
    Lazzari, A. A., Dussault, P. M., Thakore-James, M., Gagnon, D., Baker, E., Davis, S. A., & Houranieh, A. M. (2013). Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial. Epilepsia, 54(11), pp. 1997-2004. doi:10.1111/epi.12351.
    Lazzari AA, et al. Prevention of Bone Loss and Vertebral Fractures in Patients With Chronic Epilepsy--antiepileptic Drug and Osteoporosis Prevention Trial. Epilepsia. 2013;54(11):1997-2004. PubMed PMID: 24010637.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial. AU - Lazzari,Antonio A, AU - Dussault,Philip M, AU - Thakore-James,Manisha, AU - Gagnon,David, AU - Baker,Errol, AU - Davis,Samuel A, AU - Houranieh,Antoun M, Y1 - 2013/09/06/ PY - 2013/07/27/accepted PY - 2013/9/10/entrez PY - 2013/9/10/pubmed PY - 2014/1/1/medline KW - Anti-epileptic drugs KW - Bisphosphonates KW - Epilepsy KW - Fractures KW - Osteoporosis SP - 1997 EP - 2004 JF - Epilepsia JO - Epilepsia VL - 54 IS - 11 N2 - PURPOSE: To evaluate whether use of a bisphosphonate (risedronate) in addition to calcium and vitamin D in male veterans with epilepsy who were taking antiepileptic drugs (AEDs) long term can prevent the loss of bone mass (BMD, bone mineral density) associated with AED use compared to patients who were treated with a placebo plus calcium and vitamin D. As a secondary end point we studied the incidence of new morphometric vertebral and nonvertebral fractures. METHODS: Antiepileptic drug and osteoporosis prevention trial (ADOPT) was designed as a prospective 2-year double-blind, randomized placebo controlled study involving 80 male veterans with epilepsy who were being treated with AEDs such as phenytoin, phenobarbital, sodium valproate, or carbamazepine for a minimum of 2 years. All enrolled participants received calcium and vitamin D supplementation, and were randomized to risedronate or matching placebo. Total body, bilateral proximal femora, and anteroposterior (AP) lumbar spine BMDs in addition to morphometric lateral vertebral assessments (LVAs) were evaluated by a dual energy x-ray absorptiometry (DXA) instrument. Comparisons of BMDs were made between baseline, 1 year, and after 2 years of enrollment in the study. The incidence of new vertebral and nonvertebral fractures was secondary end point. KEY FINDINGS: Of the 80 patients initially enrolled in the study, 53 patients completed the study. Baseline characteristics of the two groups were similar. At the end of the study, in the placebo plus calcium and vitamin D group, we observed a significant improvement in BMD at any of the evaluated sites when compared to their baseline scans in 69% (18/26) of the participants. In the risedronate plus calcium and vitamin D group, we observed significant improvement of BMDs in 70% (19/27) of the participants. At the end of the study, the risedronate group experienced a significant increase of BMD at the lumbar spine L1-4 (1.267-1.332 g/cm(2)), which was significantly larger than that seen in the placebo group) (1.229 g/cm(2) vs. 1.245 g/cm(2) ; p = 0.0066).There were nonsignificant differences between the two groups regarding changes of total body BMD or at the proximal bilateral femora. Five new vertebral fractures and one nonvertebral fracture were observed only in the placebo group. SIGNIFICANCE: Calcium and vitamin D supplementation or calcium and vitamin D supplementation in addition to risedronate improved BMD in more than 69% of male veterans with epilepsy who were taking AEDs. In the group receiving risedronate plus calcium and vitamin D there was a significant improvement of BMD at the lumbar spine as compared to the placebo group, which also received calcium and vitamin D. The use of risedronate plus calcium and vitamin D prevented the incidence of new vertebral fractures and one nonvertebral fracture in this cohort. SN - 1528-1167 UR - https://www.unboundmedicine.com/medline/citation/24010637/full_citation L2 - https://doi.org/10.1111/epi.12351 DB - PRIME DP - Unbound Medicine ER -